Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The Chronic Plaque Psoriasis Market Size?

Over the last few years, the market size for chronic plaque psoriasis has seen robust growth. Projections suggest that it will increase from $20.79 billion in 2024, reaching $22.26 billion in 2025 – reflecting a compound annual growth rate (CAGR) of 7.0%. This historical period growth can be ascribed to the increasing instances of psoriasis, a rise in related co-morbidities, beneficial reimbursement policies, a surge in alcohol and smoking consumption, as well as the emergence of telemedicine.

The market size for chronic plaque psoriasis is predicted to witness robust expansion in the upcoming years, hitting $29.09 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period is likely due to the increasing or decreasing incidence of cpp worldwide, the surge in autoimmune diseases, expansion in healthcare budgets, an aging demographic, and the growing demand for potent treatments. Key trends during this forecast timeframe include progress in biologic treatments, oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Factors Are Steering Growth In The Chronic Plaque Psoriasis Market?

The escalation in incidences of immune system malfunctions is anticipated to fuel the expansion of the market for chronic plaque psoriasis. The term refers to a scenario where the immune system ceases to function efficiently, leading to higher vulnerability to infections, autoimmune diseases, and cancer. The rise in such cases can be attributed to various aspects including genetic susceptibility, environmental triggers, malnutrition, chronic stress, and the escalating rate of autoimmune diseases and infections like HIV. Treating chronic plaque psoriasis is necessary to manage the malfunctioning immune system as it mistakenly promotes excess production of skin cells, triggering inflammation and plaque formation. For example, the National Psoriasis Foundation, a non-profit organization from the US, reported in December 2022 that over 8 million Americans suffer from psoriasis. On an international scale, this condition impacts 125 million individuals, representing 2 to 3% of the global population. Therefore, the rise in immune system dysfunctions is steering the expansion of the chronic plaque psoriasis market.

How Is The Chronic Plaque Psoriasis Market Organized By Different Segments?

The chronic plaque psoriasismarket covered in this report is segmented –

1) By Drug Class: Biologics; Small Molecule Drugs

2) By Route Of Administration: Injectable; Oral; Topical

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

What Current And Upcoming Trends Are Shaping The Chronic Plaque Psoriasis Market?

Premier businesses in the chronic plaque psoriasis market are striving to develop innovative therapeutics, such as IL-17A and IL-17F inhibitors, to improve the treatment methodology for chronic plaque psoriasis. IL-17A and IL-17F inhibitors are specifically designed biologic treatments that aim to hinder interleukin-17A and interleukin-17F, pro-inflammatory cytokines associated with the immune response, in order to minimize inflammation in autoimmune diseases like chronic plaque psoriasis. For example, UCB S.A., a Belgium-based biopharmaceutical firm, disclosed in October 2023, that U.S. Food and Drug Administration (FDA) granted approval for BIMZELX (bimekizumab-bkzx) to be used by adults with moderate to severe plaque psoriasis who qualify for systemic therapy or phototherapy. Bimekizumab is a unique medication designed specifically for psoriasis that targets and impedes interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two significant cytokines involved in inflammation. This approval was supported by evidence from three Phase 3 trials—BE READY, BE VIVID, and BE SURE—that evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

Who Are The Most Influential Companies In The Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Region Dominates The Chronic Plaque Psoriasis Market Today?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2025, By The Business Research Company

Psoriasis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model